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Summary.-Previous studies have characterized the enzymatic properties and
inhibition of a trypsin-like neutral protease on the surface of Ehrlich ascites cells by
means of kinetic analysis. The present study links these kinetic studies with the
recently reported role of a tumour-cell membrane-bound serine protease in tumour-
induced target cell lysis. Low-mol.-wt inhibitors of this cell-surface trypsin-like
neutral protease exhibited a corresponding ability to prevent tumour-induced
haemolysis. High-mol.-wt inhibitors of trypsin in free solution had no inhibitory
action either on the tumour-bound enzyme or on the ability of tumour cells to lyse
erythrocytes. Fragments of tumour-cell membrane retain both the trypsin-like
neutral protease activity and the ability for haemolysis. This study represents a
correlation between an easily assayed membrane-bound enzyme on tumour cells
and a function of possible biological relevance.
EARLIER STUDIES with Ehrlich ascites
tumour cells grown in mice (Steven et al.,
1980; Short et al., 1981) demonstrated that
these cells possessed a trypsin-like neutral
protease located on the cell surface. This
neutral protease was further demonstrated
to be protected from the approach ofhigh-
mol.-wt inhibitors of trypsin but was
inhibited by peptides derived by pronase
digestion of these high-mol.-wt inhibitors
(Steven & Griffin, 1982). It was concluded
that low-mol.-wt reagents which specifi-
cally inhibited this neutral protease on the
surface oftumour cells might be capable of
inhibiting the tumourigenic activity of
such cells (Steven & Griffin, 1982). It has
recently become possible to test such a
theory, employing the tumour-induced
erythrocyte-cytolysis assay introduced by
DiStefano et al. (1982). These authors
reported a membrane-bound trypsin-like
enzyme on the surface of Walker 256
tumour cells which caused haemolysis of
erythrocytes at 37°C after a lag period of
6 h in which no lysis was observed. The
activity of this protease was much higher
in a preparation oftumour-cell membranes
than in preparation ofintact tumour cells.
This observation was in contrast to an
earlier report by Zucker & Lysik (1977) in
which it was claimed that tumour-
mediated cytotoxicity of erythroblasts
required intact tumour cells. Our results
clearly show that the presence of intact
viable tumour cells is not a necessary
requirement for target-cell lysis. Washed
fragments of tumour-cell membrane are
sufficientperse to promote target-cell lysis.
All that the intact tumour cell provides is
a suitably located neutral protease on its
plasma membrane. Questions relating to
the viability of the tumour cell and the
possible effect of inhibitors used in these
studies on the tumour-cell DNA can be
disregarded as irrelevant to a discussion of
control of tumour-cell-induced lysis of
target cells, since fragments oftumour-cell
membranes can replace intact viable cells
in this assay.
We employed a similar haemolytic assayTUMOUR MEMBRANE-BOUND NEUTRAL PROTEASE
system, replacing the Walker 256 cells
with mouse Ehrlich ascites tumour cells in
the presence of incremental additions of
reagents which had previously been shown
to inhibit the cell-surface neutral protease
(Short et al., 1981; Steven et al., 1982). Our
results indicate that metal-ion inhibition
ofthe neutral proteasc on the tumour cells
corresponds to a similar inhibition of
haemolysis by tumour cells. Our evidence
also indicates that the cell-surface neutral
protease is directly responsible for the
observed haemolysis and that there is no
requirement for the release of soluble
proteases from the tumour cell to promote
lysis.
MATERIALS AND METHODS
Ehrlich ascites tumour cells were grown in
mice (Itzhaki, 1972) and harvested after 8
days. The ascitic plasma was removed by
centrifugation and the cells (> 95% of the
cells being tumour cells) washed 3 x in a large
excess of physiological saline and centrifuged
to give a pellet of washed cells. The washed
tumour cells were resuspended in 0.9% NaCl
and a cell count performed. The volume of
fluid containing tumour cells was then
adjusted to provide a suspension of cells
having 5 x 108cells/ml.Apreparationofcell-
membrane fragments was made by freezing
washed tumour cells followed by thawing and
sonicating in 0.9% NaCl. The sonicated cells
membranes were then centrifuged on a bench
centrifuge, 100g, for 5 min to remove intact
cells; the supernatant fraction containing the
disrupted cell membranes was then centri-
fuged at 120,000 g for 1 h to collect a pellet of
cell-membrane fragments. The pellet was
washed by centrifugation in 0.9% NaCl 2 x
and finally a suspension of membrane
fragments in NaCl containing 30 mg
protein/ ml was prepared.
Fresh normal human blood was suspended
without anticoagulant in a large volume of
0-9% NaCl and rapidly centrifuged to remove
plasma constituents. The erythrocytes were
carefully washed 3 x in0.9% NaCl andfinally
suspended in a medium containing 2mM
glucose dissolved in 0.9% NaCl. The erythro-
cyte count ofthis suspension was adjusted to
provide 109 cells/ml. Fresh human serum
was also obtained from these donors.
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Aprotinin supplied as the drug trasylol
(10,000 k.i.u./ml) was kindly provided by
Bayer. The gold-containing anti-rheumatic
drug Auranofin used in this study was
donated by Smith, Kline and French Ltd;
this was dissolved in water to give a stock
solution containing 10 mg Auranofin/ml. The
chemical structure ofAuranofin is S-(triethyl-
phosphoranediylaurio)- 1 -thio - fi - D - gluco-
pyranose 2,3,4,6-tetra-acetate.
All reactions were carried out in screw-
capped plastic bijou tubes. In each tube was
placed 0 5 ml tumour-cell suspension or cell-
membrane fragments, 2 ml of 2mm glucose-
NaCl, plus 0-5 ml erythrocyte suspension. The
incremental addition of potential inhibitors
was made with a 0-100,ul microsyringe. The
contents ofthe tubes were mixed and allowed
to stand without shaking at 370C for 18 h.
The contents ofthe tubes were then stirred
and centrifuged for 3 minat 200 g. Therelease
of haemoglobin from the erythrocytes was
measured by withdrawing lOO,ulaliquotsfrom
the clear supernatant fractions of each tube
and placing this sample in 3 ml 0.9% NaCl
before spectrometric analysis at 530 nm, the
isosbestic point of haemoglobin and meth-
aemoglobin (Joiner & Lauf, 1978). The total
haemoglobin content ofthe erythrocytes was
determined on control tubes to which 100 ,tg
of saponin had been added. We decided to
arrange conditions so that the added tumour
cells caused between 30 and 40% total
haemolysis. The inhibition of tumour-cell-
induced haemolysis is presented as a percent-
age of the effective haemolysis by tumour
cellsintheabsence ofpotentialinhibitors. For
example, if the tumour cells caused 38%
haemolysis, then we would give this control
the value of 100 on the vertical scale of Figs
1-3, whilstthe horizontal axisdefinesthefinal
concentration ofpotential inhibitor inthetest
system, having a total volume of 3 ml. In
order to demonstrate that the intact living
tumour cells were not a requirement for
target-cell cytolysis, we employed a similar
incremental addition of cell-membrane frag-
ments to erythrocytes in 3 ml 0.9% NaCl
containing 2mM glucose and incubated this
mixture for 18 h at 370C. Haemolysis was
measured as described above, and in this case
the degree ofhaemolysis (Fig. 4) is presented
as a percentage of the total haemolysis
obtained by adding 100 ,ug of saponin to the
control tubes in which no tumour-cell
fragments were included.
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The viability of the tumour cells in 0.9%
NaCl containing 2mM glucose and incubated
for 2 h at 37°C in the presence of potential
inhibitors of target cell cytolysis was deter-
mined by the exclusion oftrypan blue.
RESULTS
The results presented in Figs 1-3 were
taken in each case from a single experi-
mental run. The data were obtained from
24 individual tubes which constitute an
experimental run and contained (i) control
tubes with no tumour cells, (ii) control
tubes with tumour cells plus erythrocytes,
(iii) control tubes with potential inhibitor
and erythrocytes, and (iv) tubes with
tumour cells plus incremental additions of
potential inhibitor plus erythrocytes. For
each potential inhibitor (e.g. Auranofin,
etc.), 4 separate experimental runs were
performed with fresh tumour cells and
erythrocytes. The data obtainedfrom each
ofthese was plotted as aninhibitiongraph,
only 1 ofwhich is presented in Figs 1-3, as
being representative ofthe 4. The 4 graphs
closely approximated (within + 5%) to
that presented in each figure.
The viability of control tumour cells
after 2h incubation was of the same order
as the viability of tumour cells in the
presence of potential inhibitors as shown
in the Table.
Fresh human serum (up to 200 ul/tube
or 66 pl/ml) and aprotinin (up to 200
pl/tube, or 2000 k.i.u./tube) had no
inhibitory action on the haemolytic activ-
ity of Ehrlich ascites tumour cells (Fig. 1,
TABLE-Viability of tumour cells after 2 h
at 37°C assayed by trypan-blue, uptake
Test systems
Control tumour cells
Tumour cells plus
Tumour cells plus
Tumour cells plus
Tumour cells plus
Tumour cells plus
Tumour cells plus
Tumour cells plus
Tumour cells plus
Inhibitor Viability*
55
50 FM Auranofin 55
100 jM Auronofin 55
150 tM Auronofin 55
0 5 mM ZnSO4 67
1*0 mM ZnSO4 54
0 5 mM ZnSO4 56
3 0 mM ZnSO4 53
3* 5 mM ZnSO4 59
* Expressed as % of total cells counted.
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FIG. 1.-Haemolysis by tumour cell8 in the
presence of serum, aprotinin and Auranofin.
Nonspecific inhibitors of proteases such
as human serum and aprotinin has no effect
on the rupture of erythrocytes by tumour
cells (dotted line). Auranofin, capable of
inhibiting tumour-cell-surface neutral pro-
tease, was an effective inhibitor oferythro-
cyte lysis by added tumour cells (curve).
dotted line). Low-mol.-wt inhibitors ofthe
tumour-cell-surface neutral protease, e.g.
Auranofin and zinc ions, exhibited a
marked inhibitory action on tumour-
induced haemolysis oferythrocytes (Figs 1
& 2). In these experiments the pH
remained virtually constant throughout
(pH 6.3) and only 1-2% of the erythro-
cytes lysed in the absence of tumour cells.
When free trypsin (20 ug/tube) was added
to the controls containing no tumour cells,
no haemolysis was demonstrated.
When cell-membrane fragments were
employed in place ofintact viable tumour
cells, target-cell lysis could readily be
demonstrated (Figs 3 & 4). Lysis induced
by tumour-cell-membrane fragments was
also inhibited by Auranofin and ZnSO4;
the data for ZnSO4 are presented in Fig. 3.
In order to demonstrate that lysis was
independent of the presence of viable
tumour cells, we employed incremental
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FIG. 2.-Haemolysi8 by tumour cells in the,
presence of zinc ion8. Zinc ions which
inhibit the tumour-cell surface neutral
protease also inhibit erythrocyte lysis
by added tumour cells.
additions of tumour-cell-membrane frag-
ments to a fixed number of erythrocytes
and showed a direct relationship between
the degree ofhaemolysis and the quantity
ofwashed membrane protein added to the
system (Fig. 4).
DISCUSSION
Although we report the viability of
tumour cells under our experimental
conditions, the data in Figs. 3 & 4 make
the discussion of cell viability irrelevant.
The results clearly indicate thathigh-mol.-
wt inhibitors of proteolytic enzymes, viz.
serum proteins, rich in ax2-macroglobulin
and 6 other trypsin-like enzyme inhibitors
(Heimburger, 1975) failed to inhibit
tumour-induced haemolysis as would be
predicted from our earlier studies.
Similarly the reagent aprotinin (mol. wt
, 12,000; Rifkin & Crowe, 1977), with a
wide specificity for proteolytic enzymes,
failed to inhibit tumour-cell-induced
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FIG. 3.-Haemoly8i8 by tumour-cell-membrane
fragment8 in the presence of zinc ions.
Zinc ions which inhibit the tumour-cell-
membrane-bound neutral protease also
inhibit the lysis of erythrocytes by added
tumour-cell-membrane fragments (15 mg/
tube).
haemolysis. Neither serum nor aprotinin is
an effective inhibitor of the cell-surface
trypsin-like enzyme of Ehrlich ascites
tumour cells (Steven et al., 1980; Steven &
Griffin, 1982). Free trypsin was unable to
cause haemolysis, which may also indicate
that enzymes in free solution are not
responsible for the observed haemolysis.
Metalions, which have been shown to be
good inhibitors of cell-bound neutral
proteases on tumour and sperm cells
(Short etal., 1981; Steven etal., 1982) were
good inhibitors of tumour-induced
haemolysis (Figs 1-3). Itshould bepointed
out that direct comparisons cannot be
made between the molarity of metal ions
requiredto causeinhibition oftumour-cell-
surface P-naphthylamidase activity (Short
et al., 1981) and inhibition of tumour-
mediated haemolysis, since the erythro-
cytes will also bind metal ions and alter
the effective ionic concentration in the test
system. It is clear, however, that good
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FIa. 4.-Haemolys8i by incremental addi-
tions of tumour-cell-membrane fragment8.
The data show that the haemolytic
neutral protease is located on the tumour-
cell membrane and that intact viable
tumour cells are not necessary for ery-
throcyte lysis.
inhibitors of the cell-surface /-naphthyl-
amidase activity were also good inhibitors
of tumour-mediated haemolysis.
The data obtained with tumour-cell-
membrane fragments (Figs 3 & 4) confirm
the claim by DiStefano et al. (1982) that
the effective proteolytic enzyme fortarget-
cell lysis is located on the tumour-cell
membrane. It is not necessary to employ
intact tumour cells to observe target-cell
cytolysis. It can be concluded that since
cytolysis induced by tumour-cell-mem-
brane fragments (Fig. 3) can be inhibited
by Zn++, etc., these inhibitors control this
enzyme directly, rather than by influen-
cing the tumour-induced cytolysis through
modification oftumour DNA.
Zn++ is almost equally as effective in
inhibiting haemolysis by the membrane
fragments (Fig. 3) and by intact tumour
cells (Fig. 2).
We believe the results presented above
strengthen the claim made by DiStefano et
at. (1982) that tumour-induced target-cell
lysis is mediated by a membrane-bound
protease which is similar to trypsin and
which maybeassayedbythefluorescent /-
naphthylamidase assay (Short et al., 1981).
This study therefore links the previously
reported kinetic studies (Steven et al.,
1980; Short et al., 1981) ofthe tumour-cell-
surface neutral protease and the study of
its inhibition, with one of the observable
biological properties of tumour cells,
namely target cytolysis (DiStefano et al.,
1982). We believe further studies of the
selective inhibition of this important cell-
surface neutral protease could lead to
further developments in the control ofthe
biological properties of tumour cells, for
example cell lysis and the generation of
proteolytic enzymes of crucial importance
in the pathophysiology ofcancer invasion.
We wish to thank Dr William Ofosu-Appiah for
his skilful and painless removal of our blood samples
on almost every day of the last 4 months. Without
this supply of basic raw materials our study could
not have been attempted.
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